CAR T-cell therapy has proven effective in delivering high response rates in relapsed acute lymphoblastic leukemia (ALL) patients, but what can be done to move the field forward? Here, Noelle Frey, MD, from the University of Pennsylvania, Philadelphia, PA, discusses the current strategies that are being put in place to mitigate toxicity, such as the early delivery of tocilizumab and modifying the dose of CAR T-cell therapy delivered to the patient. Although the initial response rates to CAR T-cell therapy are high, this form of therapy should also be targeted towards antigens such as CD22, which would decrease the rates of CD19-negative relapse. This videos was recorded at the 2018 European School of Hematology (ESH) Clinical Updates on Acute Leukemias held in Budapest, Hungary.

свернуть